Glaxosmithkline PLC, Director at Turning Point Therapeutics, Inc. (TPTX), bought 177,777 shares at $45.00 ($8.0M) on 2019-09-10, disclosed to the SEC on 2019-09-12.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| Filing → |
| DBTX | BUY | 2021-02-19 | $2.7M | — | Filing → |
| BCYC | SELL | 2020-09-18 | $151K | — | Filing → |
| GNCA | BUY | 2020-07-30 | $2.8M | — | Filing → |